HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yi-Xin Zeng Selected Research

N-(4-ethoyphenol)-2-hydroxy- acid amide

1/2006SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yi-Xin Zeng Research Topics

Disease

145Neoplasms (Cancer)
04/2022 - 02/2002
96Nasopharyngeal Carcinoma
01/2021 - 02/2002
29Neoplasm Metastasis (Metastasis)
11/2021 - 06/2003
25Carcinoma (Carcinomatosis)
04/2022 - 01/2005
23Carcinogenesis
01/2022 - 06/2003
16Epstein-Barr Virus Infections
11/2022 - 06/2003
16Hepatocellular Carcinoma (Hepatoma)
01/2020 - 06/2004
15Breast Neoplasms (Breast Cancer)
07/2017 - 11/2004
10Infections
11/2022 - 09/2005
10Esophageal Squamous Cell Carcinoma
04/2013 - 09/2009
7Osteosarcoma (Osteogenic Sarcoma)
11/2021 - 08/2005
7Colorectal Neoplasms (Colorectal Cancer)
01/2014 - 07/2005
6Lung Neoplasms (Lung Cancer)
01/2022 - 01/2003
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2021 - 10/2005
5Lymphatic Metastasis
06/2014 - 10/2006
5Cystadenoma
01/2013 - 01/2005
5Colonic Neoplasms (Colon Cancer)
01/2012 - 04/2008
5Leukemia
11/2011 - 02/2002
4Inflammation (Inflammations)
01/2022 - 07/2010
4Liver Neoplasms (Liver Cancer)
01/2020 - 07/2004
3Glioblastoma (Glioblastoma Multiforme)
10/2021 - 12/2009
3Neuroblastoma
10/2017 - 02/2010
3Melanoma (Melanoma, Malignant)
05/2017 - 09/2013
3Lymphoma (Lymphomas)
09/2015 - 02/2006
3Disease Progression
03/2013 - 11/2008
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 09/2015
2Glioma (Gliomas)
01/2020 - 05/2017
2Kidney Neoplasms (Kidney Cancer)
11/2017 - 05/2017
2Chronic Hepatitis B
08/2017 - 06/2010
2Ovarian Neoplasms (Ovarian Cancer)
05/2017 - 07/2011

Drug/Important Bio-Agent (IBA)

47Proteins (Proteins, Gene)FDA Link
01/2022 - 06/2003
16DNA (Deoxyribonucleic Acid)IBA
01/2019 - 06/2003
15AntibodiesIBA
01/2019 - 03/2004
14Messenger RNA (mRNA)IBA
07/2012 - 01/2003
13Biomarkers (Surrogate Marker)IBA
01/2019 - 11/2004
11AntigensIBA
03/2021 - 03/2004
11Indicators and Reagents (Reagents)IBA
01/2019 - 11/2004
8Biological ProductsIBA
01/2018 - 07/2010
8MicroRNAs (MicroRNA)IBA
11/2016 - 11/2008
7VaccinesIBA
11/2022 - 09/2005
7Telomerase (Telomerase Reverse Transcriptase)IBA
10/2021 - 02/2006
7Phosphotransferases (Kinase)IBA
01/2020 - 05/2005
7Immunoglobulin A (IgA)IBA
04/2018 - 03/2004
7Small Interfering RNA (siRNA)IBA
01/2018 - 02/2006
6Peptides (Polypeptides)IBA
01/2020 - 01/2007
6EnzymesIBA
02/2013 - 03/2004
5Neutralizing AntibodiesIBA
11/2022 - 12/2010
5CytokinesIBA
11/2019 - 10/2012
5LigandsIBA
05/2018 - 06/2005
5Membrane Proteins (Integral Membrane Proteins)IBA
07/2017 - 02/2002
4Glycoproteins (Glycoprotein)IBA
03/2021 - 02/2015
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2018 - 05/2002
4CateninsIBA
11/2015 - 12/2011
4ImmunosorbentsIBA
02/2013 - 03/2004
4Oncogene Proteins (Oncogene Protein)IBA
03/2010 - 06/2006
3ErbB Receptors (EGF Receptor)IBA
01/2022 - 10/2009
3EpitopesIBA
01/2022 - 01/2020
3Paclitaxel (Taxol)FDA LinkGeneric
10/2021 - 10/2014
3HLA Antigens (Human Leukocyte Antigens)IBA
12/2018 - 04/2011
3Pharmaceutical PreparationsIBA
07/2017 - 05/2002
3Interleukin-6 (Interleukin 6)IBA
07/2017 - 10/2012
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2015 - 01/2006
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2015 - 05/2005
3Fatty Acids (Saturated Fatty Acids)IBA
06/2014 - 01/2006
3Tumor Biomarkers (Tumor Markers)IBA
05/2014 - 06/2003
3Cisplatin (Platino)FDA LinkGeneric
02/2013 - 11/2008
3Insulin-Like Growth Factor Binding Protein 3IBA
12/2012 - 08/2012
3Histones (Histone)IBA
01/2011 - 05/2008
3Enhancer of Zeste Homolog 2 ProteinIBA
09/2010 - 07/2010
3ClusterinIBA
06/2010 - 01/2005
3Caspase 3 (Caspase-3)IBA
08/2009 - 02/2002
3eIF-5A2IBA
05/2009 - 02/2009
3Mitochondrial DNA (mtDNA)IBA
02/2008 - 06/2004
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
04/2022 - 06/2009
2Tumor Suppressor Protein p14ARF (p14ARF)IBA
01/2022 - 06/2010
2Glucose (Dextrose)FDA LinkGeneric
10/2021 - 11/2012
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
03/2021 - 01/2019
2SaltsIBA
01/2021 - 08/2010
2TeaIBA
01/2021 - 12/2010
2Imatinib Mesylate (Gleevec)FDA Link
11/2020 - 11/2009
2Hepatitis B Core AntigensIBA
01/2020 - 11/2015
2Antiviral Agents (Antivirals)IBA
11/2019 - 01/2016
2Beclin-1IBA
10/2017 - 01/2013
2Aurora Kinase AIBA
08/2017 - 08/2009
2RNA (Ribonucleic Acid)IBA
02/2017 - 06/2003
2BilirubinIBA
02/2016 - 03/2015
2AgarIBA
01/2016 - 06/2010
2Neuropilin-1IBA
09/2015 - 02/2015
2Cyclin D1IBA
11/2013 - 12/2009
2Carrier Proteins (Binding Protein)IBA
04/2013 - 07/2007
2ParaffinIBA
01/2013 - 12/2012
2nimotuzumabIBA
12/2012 - 08/2012
2Interleukin-8 (Interleukin 8)IBA
10/2012 - 07/2012
2Syk KinaseIBA
10/2012 - 06/2012
2S-Phase Kinase-Associated Proteins (Skp1 Protein)IBA
05/2012 - 03/2011

Therapy/Procedure

22Therapeutics
01/2022 - 11/2004
14Drug Therapy (Chemotherapy)
01/2017 - 05/2002
14Radiotherapy
01/2016 - 06/2003
10Immunotherapy
01/2022 - 01/2005
6Chemoradiotherapy
02/2015 - 09/2009